Table 1 Participant characteristics
Total (n = 10) | Better response group (n = 5) | Poorer response group (n = 5) | Between group difference p-value, effect size r | |
|---|---|---|---|---|
Sex, male / female | 9 / 1 | 4 / 1 | 5 / 0 | 1.000 |
Age | 73.50 (72.00, 80.00) | 72.00 (70.50, 84.00) | 74.00 (73.00, 77.50) | 0.310 |
Disease duration, years | 4.50 (2.00, 6.25) | 4.00 (2.25, 7.50) | 5.00 (2.00, 7.50) | 0.841 |
HY stage | 3.00 (3.00, 3.00) | 3.00 (2.50, 3.00) | 3.00 (3.00, 3.00) | 0.690 |
UPDRS-III | 36.00 (14.00, 49.75) | 15.00 (11.00, 39.00) | 45.00 (31.00, 62.50) | 0.095 |
NFOGQ | 26.50 (21.75, 28.00) | 22.00 (17.50, 24.50) | 28.00 (27.50, 28.00) | 0.008, − 0.852* |
K-MMSE | 26.50 (24.00, 28.00) | 28.00 (24.50, 29.00) | 26.00 (23.50, 27.50) | 0.310 |
RRO | 0.33 (0.19, 0.69) | 0.67 (0.50, 0.83) | 0.22 (0.06, 0.28) | 0.008, − 0.800* |
RRD | 0.19 (-0.08, 0.48) | 0.48 (0.38, 0.54) | −0.06 (-0.15, 0.02) | 0.008, − 0.826* |
RRP, % | 4.95 (-10.13, 15.40) | 15.38 (9.43, 20.09) | −8.36 (-15.47, 2.54) | 0.008, -0.826* |